{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:49:58Z","timestamp":1790383798536,"version":"4.1.0"},"reference-count":177,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.heliyon.2022.e09575","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T02:04:57Z","timestamp":1654308297000},"page":"e09575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8458-4546","authenticated-orcid":false,"given":"Sureshbabu Ram Kumar","family":"Pandian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8761-3242","authenticated-orcid":false,"given":"Kevin Kumar","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-1577","authenticated-orcid":false,"given":"Sankaranarayanan","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraj","family":"Kunjiappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2022.e09575_bib1","series-title":"Neurological Disorders: Public Health Challenges","year":"2006"},{"key":"10.1016\/j.heliyon.2022.e09575_bib2","doi-asserted-by":"crossref","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib3","doi-asserted-by":"crossref","DOI":"10.31887\/DCNS.2003.5.1\/chock","article-title":"Biochemical aspects of dementias","volume":"5","author":"Hock","year":"2003","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib4","doi-asserted-by":"crossref","unstructured":"Krstic,D. and Knuesel,I. (2013) Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol., 9, 25\u201334.","DOI":"10.1038\/nrneurol.2012.236"},{"key":"10.1016\/j.heliyon.2022.e09575_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer's disease and the amyloid-\u03b2 peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.heliyon.2022.e09575_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.fshw.2021.12.006","article-title":"Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer's disease: an overview of pre-clinical studies focused on \u03b2-amyloid peptide","volume":"11","author":"Youn","year":"2022","journal-title":"Food Sci. Hum. Wellness"},{"key":"10.1016\/j.heliyon.2022.e09575_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid \u03b2-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib8","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.008207","article-title":"The essential elements of Alzheimer's disease","volume":"296","author":"Lei","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.heliyon.2022.e09575_bib9","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.heliyon.2022.e09575_bib11","article-title":"Nanoparticles as powerful tools for crossing the blood-brain barrier","author":"Hasannejad-Asl","year":"2022","journal-title":"CNS Neurol. Disord. Targets (Formerly Curr. Drug Targets-CNS Neurol. Disord."},{"key":"10.1016\/j.heliyon.2022.e09575_bib12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2217\/nnm.14.206","article-title":"Nanomedicine for the treatment of Alzheimer's disease","volume":"10","author":"Gregori","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.heliyon.2022.e09575_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00441-008-0658-9","article-title":"Brain endothelial cells and the glio-vascular complex","volume":"335","author":"Wolburg","year":"2009","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01511-z","article-title":"The blood-brain barrier in aging and neurodegeneration","author":"Knox","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.heliyon.2022.e09575_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/320941","article-title":"Blood-brain barrier: a challenge for effectual therapy of brain tumors","volume":"2015","author":"Bhowmik","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.heliyon.2022.e09575_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cbpa.2017.04.019","article-title":"Blood\u2013brain barrier peptide shuttles","volume":"38","author":"S\u00e1nchez-Navarro","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-022-00312-4","article-title":"The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments","volume":"19","author":"Sol\u00e1r","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.heliyon.2022.e09575_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.heliyon.2022.e09575_bib19","series-title":"Seminars in Cancer Biology","article-title":"Current nano-therapeutic approaches ameliorating inflammation in cancer progression","author":"Rehman","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e09575_bib20","article-title":"Nanomaterials for Parkinson disease: recent progress","author":"Ghazy","year":"2020","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.heliyon.2022.e09575_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.20517\/evcna.2022.04","article-title":"Engineered mammalian and bacterial extracellular vesicles as promising nanocarriers for targeted therapy","volume":"3","author":"Liu","year":"2022","journal-title":"Extracell. Vesicles Circ. Nucleic Acids"},{"key":"10.1016\/j.heliyon.2022.e09575_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146738","article-title":"Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes","volume":"1734","author":"dos Santos Rodrigues","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/acschemneuro.7b00312","article-title":"Sulfur nanoparticles with novel morphologies coupled with brain-targeting peptides RVG as a new type of inhibitor against metal-induced a\u03b2 aggregation","volume":"9","author":"Sun","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib24","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.2147\/IJN.S203330","article-title":"Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells","volume":"14","author":"Lujan","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.heliyon.2022.e09575_bib25","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","article-title":"Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic","volume":"26","author":"Puri","year":"2009","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.heliyon.2022.e09575_bib26","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.2147\/IJN.S117210","article-title":"Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier","volume":"11","author":"Vieira","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.heliyon.2022.e09575_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib28","article-title":"Liposomes for brain delivery","volume":"10","author":"Lai","year":"2013","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-022-03241-x","article-title":"Targeting transporters for drug delivery to the brain: can we do better?","author":"Puris","year":"2022","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.heliyon.2022.e09575_bib30","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0006-291X(88)81333-0","article-title":"Liposome targeting to mouse brain: mannose as a recognition marker","volume":"153","author":"Umezawa","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2022.e09575_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","article-title":"Ligand-targeted liposome design: challenges and fundamental considerations","volume":"32","author":"Noble","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib32","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.2147\/IJN.S183117","article-title":"Liposome delivery systems for the treatment of Alzheimer's disease","volume":"13","author":"Ross","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.heliyon.2022.e09575_bib33","article-title":"Targeting with nanoparticles for the therapeutic treatment of brain diseases","volume":"11","author":"Jin","year":"2020","journal-title":"J.\u00a0Tissue Eng."},{"key":"10.1016\/j.heliyon.2022.e09575_bib34","doi-asserted-by":"crossref","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11481-006-9025-3","article-title":"Blood-brain barrier: structural components and function under physiologic and pathologic conditions","volume":"1","author":"Persidsky","year":"2006","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2008.10.022","article-title":"The blood-brain barrier in brain homeostasis and neurological diseases","volume":"1788","author":"Weiss","year":"2009","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.heliyon.2022.e09575_bib37","first-page":"262","article-title":"Structure, function, and regulation of cellular tight junctions","author":"Schneeberger","year":"1992","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/35067088","article-title":"Multifunctional strands in tight junctions","volume":"2","author":"Tsukita","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.heliyon.2022.e09575_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01346","article-title":"Astrocyte-derived paracrine signals: relevance for neurogenic niche regulation and blood-brain barrier integrity","volume":"10","author":"Spampinato","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib41","series-title":"Micro-and Nano-Containers for Smart Applications","first-page":"309","article-title":"Containers based drug delivery for neuroscience","author":"Jose","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e09575_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.heliyon.2022.e09575_bib43","doi-asserted-by":"crossref","DOI":"10.1124\/mi.3.2.90","article-title":"Blood-brain barrier drug targeting: the future of brain drug development","volume":"3","author":"Pardridge","year":"2003","journal-title":"Mol. Interv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202004025","article-title":"Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood-brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release","volume":"8","author":"Ruan","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s40089-017-0208-0","article-title":"Nanotechnology and nano carrier-based approaches on treatment of degenerative diseases","volume":"7","author":"Chowdhury","year":"2017","journal-title":"Int. Nano Lett."},{"key":"10.1016\/j.heliyon.2022.e09575_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40820-022-00847-z","article-title":"Anti-parkinsonian therapy: strategies for crossing the blood-brain barrier and nano-biological effects of nanomaterials","volume":"14","author":"Cheng","year":"2022","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.heliyon.2022.e09575_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-022-00902-w","article-title":"Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy","author":"Mukherjee","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.heliyon.2022.e09575_bib48","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-022-01228-5","article-title":"Current chemical, biological, and physiological views in the development of successful brain-targeted pharmaceutics","author":"Markowicz-Piasecka","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.heliyon.2022.e09575_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2017.05.019","article-title":"Recent advancements in liposomes targeting strategies to cross the blood-brain barrier (BBB) for the treatment of Alzheimer's disease","volume":"260","author":"Agrawal","year":"2017","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib50","article-title":"Development and stability studies of novel liposomal vancomycin formulations","volume":"2012","author":"Muppidi","year":"2012","journal-title":"ISRN Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib51","series-title":"Purification Method of Drug-Loaded Liposome","author":"Lin","year":"2021"},{"key":"10.1016\/j.heliyon.2022.e09575_bib52","article-title":"Liposomal formulation of chondroitin sulfate enhances its antioxidant and anti-inflammatory potential in L929 fibroblast cell line","volume":"23","author":"Craciunescu","year":"2013","journal-title":"J.\u00a0Liposome Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2016.09.027","article-title":"Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs","volume":"514","author":"Joshi","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib54","article-title":"Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation","volume":"20","author":"Jaafar-Maalej","year":"2010","journal-title":"J.\u00a0Liposome Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib55","article-title":"A\u00a0comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents","author":"Andra","year":"2022","journal-title":"Bionanoscience"},{"key":"10.1016\/j.heliyon.2022.e09575_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2016.08.033","article-title":"Development of risperidone liposomes for brain targeting through intranasal route","volume":"163","author":"Narayan","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.tifs.2016.06.012","article-title":"Liposomal microencapsulation using the conventional methods and novel supercritical fluid processes","volume":"55","author":"Tsai","year":"2016","journal-title":"Trends Food Sci. Technol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib58","doi-asserted-by":"crossref","DOI":"10.1021\/la7020963","article-title":"Comparison of liposomes formed by sonication and extrusion: rotational and translational diffusion of an embedded chromophore","volume":"23","author":"Lapinski","year":"2007","journal-title":"Langmuir"},{"key":"10.1016\/j.heliyon.2022.e09575_bib59","doi-asserted-by":"crossref","DOI":"10.4103\/2221-1691.280297","article-title":"Free and liposome form of gallic acid improves calvarial bone wound healing in Wistar rats","volume":"10","author":"Altan","year":"2020","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.heliyon.2022.e09575_bib60","series-title":"Nanoparticle Therapeutics","article-title":"Fabrication design, process technologies, and convolutions in the scale-up of nanotherapeutic delivery systems","author":"Goel","year":"2022"},{"key":"10.1016\/j.heliyon.2022.e09575_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111633","article-title":"Advances in microfluidic synthesis and coupling with synchrotron SAXS for continuous production and real-time structural characterization of nano-self-assemblies","volume":"201","author":"Ilhan-Ayisigi","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.heliyon.2022.e09575_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/pharmaceutics14010141","article-title":"Advanced microfluidic technologies for lipid nano-microsystems from synthesis to biological application","volume":"14","author":"Carvalho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.heliyon.2022.e09575_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-007-9340-5","article-title":"Preparation of nanoparticles by continuous-flow microfluidics","volume":"10","author":"Jahn","year":"2008","journal-title":"J.\u00a0Nanoparticle Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/srep25876","article-title":"Liposome production by microfluidics: potential and limiting factors","volume":"6","author":"Carugo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2022.e09575_bib65","doi-asserted-by":"crossref","DOI":"10.1021\/ja0318030","article-title":"Controlled vesicle self-assembly in microfluidic channels with hydrodynamic focusing","volume":"126","author":"Jahn","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.heliyon.2022.e09575_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2013.06.057","article-title":"The nanostructure of surfactant-DNA complexes with different arrangements","volume":"111","author":"Mezei","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.heliyon.2022.e09575_bib67","doi-asserted-by":"crossref","DOI":"10.2174\/1381612053382133","article-title":"The design of cationic lipids for gene delivery","volume":"11","author":"Martin","year":"2005","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.heliyon.2022.e09575_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/sj.gt.3301401","article-title":"Enhanced cationic liposome-mediated transfection using the DNA-binding peptide \u03bc (mu) from the adenovirus core","volume":"8","author":"Murray","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.heliyon.2022.e09575_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/S1567-5394(02)00132-9","article-title":"Cationic lipid-DNA complexes - lipoplexes - for gene transfer and therapy","volume":"58","author":"Zhdanov","year":"2002","journal-title":"Bioelectrochemistry"},{"key":"10.1016\/j.heliyon.2022.e09575_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2022.e09575_bib71","doi-asserted-by":"crossref","DOI":"10.1054\/bjoc.2000.1459","article-title":"High intratumoural accumulation of stealth\u00ae liposomal doxorubicin (Caelyx\u00ae) in glioblastomas and in metastatic brain tumours","volume":"83","author":"Koukourakis","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2022.e09575_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/nano6010003","article-title":"Receptor-mediated drug delivery systems targeting to glioma","volume":"6","author":"Wang","year":"2015","journal-title":"Nanomaterials"},{"key":"10.1016\/j.heliyon.2022.e09575_bib73","article-title":"Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: a state-of-the-art review","author":"Kunjiappan","year":"2020","journal-title":"Drug Dev. Res., n\/a."},{"key":"10.1016\/j.heliyon.2022.e09575_bib74","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/pharmaceutics14030672","article-title":"Strategies for targeted delivery of exosomes to the brain: advantages and challenges","volume":"14","author":"Choi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.heliyon.2022.e09575_bib75","article-title":"Ligand-installed nanocarriers toward precision therapy","volume":"32","author":"Mi","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.heliyon.2022.e09575_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.heliyon.2022.e09575_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2007.06.008","article-title":"Endocytic mechanisms for targeted drug delivery","volume":"59","author":"Bareford","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2022.e09575_bib79","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","DOI":"10.1016\/bs.apha.2014.06.001","article-title":"Transcytosis of macromolecules at the blood-brain barrier","volume":"71","author":"Preston","year":"2014"},{"key":"10.1016\/j.heliyon.2022.e09575_bib80","article-title":"Pharmacokinetic aspects of biotechnology products","volume":"93","author":"Tang","year":"2004","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/hrt.2008.152652","article-title":"Amiodarone: an effective antiarrhythmic drug with unusual side effects","volume":"96","author":"Van Erven","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.heliyon.2022.e09575_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.heliyon.2022.e09575_bib83","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/aac9ec","article-title":"Preparation of liposomes encapsulated Epirubicin-gold nanoparticles for Tumour-specific delivery and release","volume":"4","author":"Kunjiappan","year":"2018","journal-title":"Biomed. Phys. Eng. Express"},{"key":"10.1016\/j.heliyon.2022.e09575_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2014.04.015","article-title":"Nano-niosomes as nanoscale drug delivery systems: an illustrated review","volume":"185","author":"Moghassemi","year":"2014","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2016.02.019","article-title":"Lipid-based nanoformulations for peptide delivery","volume":"502","author":"Matougui","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.heliyon.2022.e09575_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120346","article-title":"LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy","volume":"597","author":"d'Avanzo","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060559","article-title":"Liposome-embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy","volume":"12","author":"Cevenini","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.heliyon.2022.e09575_bib89","doi-asserted-by":"crossref","DOI":"10.2174\/1567201812666151027142412","article-title":"Hesperetin liposomes for cancer therapy","volume":"13","author":"Wolfram","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201400738","article-title":"Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response","volume":"4","author":"Kirui","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.heliyon.2022.e09575_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2014.12.008","article-title":"Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy","volume":"199","author":"Pasut","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2004.08.001","article-title":"Delivery of therapeutic agents to the central nervous system: the problems and the possibilities","volume":"104","author":"Begley","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2022.e09575_bib93","first-page":"161","article-title":"Transport of drugs across the blood-brain barrier by nanoparticles","author":"Wohlfart","year":"2012","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/pharmaceutics14020279","article-title":"Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma","volume":"14","author":"Ramalho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.heliyon.2022.e09575_bib95","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.heliyon.2022.e09575_bib96","doi-asserted-by":"crossref","DOI":"10.1186\/s11671-016-1676-2","article-title":"Passage of magnetic tat-conjugated Fe3O4@SiO2 nanoparticles across in vitro blood-brain barrier","volume":"11","author":"Zhao","year":"2016","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.heliyon.2022.e09575_bib97","article-title":"Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery","volume":"53","author":"Adenot","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.heliyon.2022.e09575_bib98","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-021-02093-9","article-title":"Geniposide-loaded liposomes for brain targeting: development, evaluation, and in vivo studies","volume":"22","author":"Wan","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.heliyon.2022.e09575_bib99","article-title":"Alzheimer's disease facts and figures (2020)","volume":"16","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.heliyon.2022.e09575_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.heliyon.2022.e09575_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/joim.12759","article-title":"Targeting Alzheimer's disease with gene and cell therapies","volume":"284","author":"Loera-Valencia","year":"2018","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.heliyon.2022.e09575_bib102","article-title":"Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib103","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.46.6.1592","article-title":"Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, part XV","volume":"46","author":"Ellis","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2022.e09575_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/ana.21696","article-title":"Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age","volume":"65","author":"Kok","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib105","doi-asserted-by":"crossref","DOI":"10.1602\/neurorx.2.1.54","article-title":"Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems","volume":"2","author":"Tsuji","year":"2005","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.heliyon.2022.e09575_bib106","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.0c00461","article-title":"Design and validation of liposomal ApoE2 gene delivery system to evade blood-brain barrier for effective treatment of alzheimer's disease","volume":"18","author":"Arora","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib107","first-page":"31","article-title":"Lipid-based nanoparticles with high binding affinity for amyloid-\u03921-42 peptide","author":"Gobbi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.heliyon.2022.e09575_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2011.05.004","article-title":"Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model","volume":"7","author":"Re","year":"2011","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.heliyon.2022.e09575_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2013.12.001","article-title":"Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect A\u03b2 aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease","volume":"10","author":"Bana","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.heliyon.2022.e09575_bib110","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.0284-14.2014","article-title":"Multifunctional liposomes reduce brain \u03b2-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models","volume":"34","author":"Balducci","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2015.02.012","article-title":"Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease","volume":"203","author":"Rotman","year":"2015","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib112","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-021-02072-0","article-title":"Development of imatinib mesylate-loaded liposomes for nose to brain delivery: in vitro and in vivo evaluation","volume":"22","author":"Saka","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.heliyon.2022.e09575_bib113","article-title":"Multifunctional osthole liposomes and brain targeting functionality with potential applications in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"Ni","year":"2021","journal-title":"J.\u00a0Liposome Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.pjnns.2017.11.009","article-title":"The relation between plasma \u03b1-synuclein level and clinical symptoms or signs of Parkinson's disease","volume":"52","author":"Malec-Litwinowicz","year":"2018","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib115","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.4423-08.2009","article-title":"Activity of neurochemically heterogeneous dopaminergic neurons in the substantia nigra during spontaneous and driven changes in brain state","volume":"29","author":"Brown","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib116","first-page":"261","article-title":"Ultrasound targeted CNS gene delivery for Parkinson's Disease Treatment","author":"Fan","year":"2017","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib117","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.8b08983","article-title":"Mechanistic understanding of the interactions between nano-objects with different surface properties and \u03b1-synuclein","volume":"13","author":"Mohammad-Beigi","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.heliyon.2022.e09575_bib118","first-page":"321","article-title":"Ultrasound-responsive neurotrophic factor-loaded microbubble- liposome complex: preclinical investigation for Parkinson\u2019s disease treatment","author":"Lin","year":"2020","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2022.e09575_bib120","article-title":"Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy","volume":"12","author":"Sampaio","year":"2017","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib121","article-title":"Neurotrophic factor-based strategies to enhance survival and differentiation of neural progenitor cells toward the dopaminergic phenotype","volume":"4","author":"Di Santo","year":"2018","journal-title":"Brain Circ."},{"key":"10.1016\/j.heliyon.2022.e09575_bib122","doi-asserted-by":"crossref","DOI":"10.1038\/350230a0","article-title":"BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra","volume":"350","author":"Hyman","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2022.e09575_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-020-0742-4","article-title":"Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson\u2019s disease","volume":"26","author":"Kahana","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.heliyon.2022.e09575_bib124","doi-asserted-by":"crossref","DOI":"10.1159\/000323222","article-title":"Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice","volume":"87","author":"Ying","year":"2011","journal-title":"Pharmacology"},{"key":"10.1016\/j.heliyon.2022.e09575_bib125","article-title":"Liposomal nanomedicines","volume":"5","author":"Fenske","year":"2008","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib126","article-title":"Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison","volume":"20","author":"Koning","year":"2003","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.heliyon.2022.e09575_bib127","article-title":"Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification","volume":"21","author":"Nellis","year":"2005","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.heliyon.2022.e09575_bib128","first-page":"1711","article-title":"Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity","author":"Laginha","year":"2005","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.heliyon.2022.e09575_bib129","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/20\/33\/335101","article-title":"Dual targeting of a thermosensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release","volume":"20","author":"Quan","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/j.heliyon.2022.e09575_bib130","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/21\/41\/415103","article-title":"Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes","volume":"21","author":"Meng","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.heliyon.2022.e09575_bib131","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2017.1396384","article-title":"Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer","volume":"24","author":"Ke","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2018.08.006","article-title":"Dual-targeting for brain-specific liposomes drug delivery system: synthesis and preliminary evaluation","volume":"26","author":"Peng","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.heliyon.2022.e09575_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.102112","article-title":"Biodistribution of TAT or QLPVM coupled to receptor-targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo","volume":"23","author":"Lakkadwala","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.heliyon.2022.e09575_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111720","article-title":"Dual-targeting liposomes with active recognition of GLUT5 and \u03b1v\u03b23 for triple-negative breast cancer","volume":"183","author":"Pu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2022.e09575_bib135","first-page":"123","article-title":"Fate and behavior of liposomes in vivo: a review of controlling factors","volume":"3","author":"Senior","year":"1987","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.heliyon.2022.e09575_bib136","article-title":"Liposomes (a review): Part two: drug delivery systems","volume":"15","author":"Chrai","year":"2002","journal-title":"BioPharm"},{"key":"10.1016\/j.heliyon.2022.e09575_bib137","article-title":"Adverse immune effects of liposomes: complement activation, immunogenicity and immune suppression","author":"Szebeni","year":"2012","journal-title":"Harnessing Biomater. Nanomed. Prep. Toxic. Appl."},{"key":"10.1016\/j.heliyon.2022.e09575_bib138","doi-asserted-by":"crossref","DOI":"10.1080\/1061186021000072447","article-title":"Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models","volume":"10","author":"Gabizon","year":"2002","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.heliyon.2022.e09575_bib139","article-title":"Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors","volume":"2","author":"Ishida","year":"2005","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/S0304-4165(01)00142-8","article-title":"Recognition and clearance of methoxy poly(ethylene glycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity: implications in experimental and clinical oncology","volume":"1526","author":"Laverman","year":"2001","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.heliyon.2022.e09575_bib141","first-page":"337","article-title":"Nanomaterials for drug delivery","author":"Hubbell","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2022.e09575_bib142","first-page":"161","article-title":"State of the art in PEGylation: the great versatility achieved after forty years of research","author":"Pasut","year":"2012","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib143","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v25.i5.10","article-title":"PEGylation: an approach for drug delivery. A review","volume":"25","author":"Jain","year":"2008","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.heliyon.2022.e09575_bib144","first-page":"1195","article-title":"Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles","author":"Parr","year":"1994","journal-title":"BBA - Biomembr."},{"key":"10.1016\/j.heliyon.2022.e09575_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2010.03.016","article-title":"Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting","volume":"145","author":"Li","year":"2010","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib146","doi-asserted-by":"crossref","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.heliyon.2022.e09575_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.molimm.2008.08.276","article-title":"Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process","volume":"46","author":"Hamad","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated Liposomes in Rats Elicits PEG-specific IgM, Which Is Responsible for Rapid Elimination of a Second Dose of PEGylated Liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib149","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.heliyon.2022.e09575_bib150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2022.e09575_bib151","doi-asserted-by":"crossref","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol-modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib152","first-page":"292","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","author":"Dams","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.heliyon.2022.e09575_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/S0378-5173(03)00085-1","article-title":"Accelerated clearance of a second injection of PEGylated liposomes in mice","volume":"255","author":"Ishida","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2006.08.001","article-title":"Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes","volume":"115","author":"Ishida","year":"2006","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.heliyon.2022.e09575_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib156","article-title":"Role of complement activation in hypersensitivity reactions to Doxil and HYNIC PEG liposomes: experimental and clinical studies","volume":"12","author":"Szebeni","year":"2002","journal-title":"J.\u00a0Liposome Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib157","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.7b00496","article-title":"Variability of complement response toward preclinical and clinical nanocarriers in the general population","volume":"28","author":"Benasutti","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.heliyon.2022.e09575_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2015.06.005","article-title":"Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells","volume":"220","author":"Shimizu","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.heliyon.2022.e09575_bib159","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib160","article-title":"Immunogenicity of polyethylene glycol based nanomedicines: mechanisms, clinical implications and systematic approach","volume":"3","author":"d'Avanzo","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.heliyon.2022.e09575_bib161","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.50","article-title":"Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents","volume":"18","author":"Szebeni","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.heliyon.2022.e09575_bib162","article-title":"Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles","volume":"17","author":"Szebeni","year":"2007","journal-title":"J.\u00a0Liposome Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2012.07.005","article-title":"A\u00a0porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines","volume":"64","author":"Szebeni","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2022.e09575_bib164","doi-asserted-by":"crossref","DOI":"10.1124\/pr.111.005223","article-title":"International union of basic and clinical pharmacology. LXXXVII. complement peptide C5a, C4a, and C3a receptors","volume":"65","author":"Klos","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.heliyon.2022.e09575_bib165","doi-asserted-by":"crossref","DOI":"10.1007\/BF01893020","article-title":"Structure and Function of the Anaphylatoxins","volume":"7","author":"Hugh","year":"1984","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib166","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.148.8.2456","article-title":"A\u00a0mechanism of action for anaphylatoxin C3a stimulation of mast cells","volume":"148","author":"Mousli","year":"1992","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.heliyon.2022.e09575_bib167","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/08982100902792855","article-title":"Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions: biological recognition and interactions of liposomes","volume":"19","author":"Szebeni","year":"2009","journal-title":"J.\u00a0Liposome Res."},{"key":"10.1016\/j.heliyon.2022.e09575_bib168","first-page":"981","article-title":"Liposomes with Prolonged Circulation Times: Factors Affecting Uptake by Reticuloendothelial and Other Tissues","author":"Allen","year":"1989","journal-title":"BBA - Biomembr."},{"key":"10.1016\/j.heliyon.2022.e09575_bib169","article-title":"Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy","volume":"8","author":"Li","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.heliyon.2022.e09575_bib170","first-page":"331","article-title":"Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes","author":"Romberg","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2008.06.004","article-title":"Particle size-dependent triggering of accelerated blood clearance phenomenon","volume":"362","author":"Koide","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2022.e09575_bib172","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2893.2003.00446.x","article-title":"Twice-weekly administration of peginterferon-\u03b1-2b improves viral kinetics in patients with chronic hepatitis C genotype 1","volume":"10","author":"Formann","year":"2003","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.heliyon.2022.e09575_bib173","article-title":"Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's Disease and Parkinson's Disease)","volume":"2011","author":"Spuch","year":"2011","journal-title":"J.\u00a0Drug Deliv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.heliyon.2022.e09575_bib175","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2018.1428243","article-title":"Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease","volume":"25","author":"Karthivashan","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.heliyon.2022.e09575_bib176","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S239608","article-title":"Transferrin-modified osthole PEGylated liposomes travel the blood-brain barrier and mitigate Alzheimer's disease-related pathology in APP\/PS-1 mice","volume":"15","author":"Kong","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.heliyon.2022.e09575_bib177","article-title":"Liposome based drug delivery as a potential treatment option for Alzheimer's disease","volume":"17","author":"Hernandez","year":"2022","journal-title":"Neural Regen. Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022008635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022008635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:05:02Z","timestamp":1776773102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022008635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":177,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2405844022008635"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09575","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e09575"}}